Can the Patient Be on Tresiba, Victoza, and NovoRapid Sliding Scale?
Yes, the patient can be on Tresiba (basal insulin) and Victoza (GLP-1 RA) together, but the NovoRapid sliding scale should be replaced with a scheduled prandial insulin regimen or eliminated entirely, as sliding scale insulin is ineffective and associated with worse glycemic outcomes.
The Combination of Tresiba and Victoza
This combination is explicitly supported and recommended:
Current guidelines strongly endorse combining basal insulin with GLP-1 receptor agonists for patients with type 2 diabetes requiring intensification 1. The 2025 ADA Standards specifically recommend considering fixed-ratio combination products (like IDegLira) when patients are on both GLP-1 RA and basal insulin 1.
Clinical evidence demonstrates superiority of this combination: When comparing the addition of liraglutide (Victoza) versus prandial insulin to insulin degludec (Tresiba), the Tresiba + Victoza combination achieved significantly greater HbA1c reduction (-0.74% vs -0.39%), with 49.4% of patients reaching HbA1c <7% without hypoglycemia or weight gain compared to only 7.2% with added prandial insulin 2.
The combination provides complementary benefits: Weight loss of -2.8 kg (vs +0.9 kg with prandial insulin), significantly less confirmed and nocturnal hypoglycemia, and better overall glycemic control 2.
The Problem with NovoRapid Sliding Scale
Sliding scale insulin should be discontinued:
Meta-analysis evidence is definitive: Sliding scale insulin (whether alone or combined with other regimens) provides no benefit in blood glucose control but significantly increases hyperglycemic events 3. The analysis of 1,322 patients across 11 RCTs showed no improvement in achieving target glucose levels but higher mean blood glucose levels (weighted mean difference = 27.33 mg/dL higher) 3.
No reduction in hypoglycemia or hospital stay: Despite theoretical concerns about hypoglycemia with more aggressive regimens, sliding scale showed no advantage in preventing severe hypoglycemia and did not reduce length of hospitalization 3.
The Correct Approach
If prandial insulin is truly needed (which is questionable given the patient is already on Victoza):
Use scheduled prandial insulin, not sliding scale: Current guidelines recommend initiating prandial insulin with one dose at the largest meal (typically 4 units or 10% of basal dose), then titrating systematically 1.
Consider the timing: If the patient has been on Tresiba + Victoza and still has inadequate control (HbA1c remains above goal), then scheduled NovoRapid with meals would be appropriate, but administered as basal-bolus therapy, not sliding scale 1.
Clinical Decision Algorithm
- If HbA1c is at goal on Tresiba + Victoza: Continue current regimen without adding prandial insulin
- If HbA1c remains elevated:
- First optimize Tresiba and Victoza doses
- If postprandial hyperglycemia persists despite optimization, add scheduled NovoRapid with the largest meal (not sliding scale)
- Start with 4 units and titrate weekly by 1-2 units based on postprandial glucose readings 1
Important Caveats
Medication interactions to monitor 4:
- The combination increases hypoglycemia risk—ensure patient has glucose monitoring and hypoglycemia education
- Monitor potassium levels as all insulins cause intracellular potassium shifts
- Watch for medication errors between insulin products—patients must check labels before each injection
When Victoza is added to insulin regimens, sulfonylureas frequently need discontinuation or dose reduction, and the Tresiba dose may need adjustment 5.
The long-acting effect of Tresiba may delay recovery from hypoglycemia compared to shorter-acting basal insulins, making proper patient education critical 4.